Researchers at the University of Auckland are seeking smokers to participate in a world-leading clinical trial of a new smoking cessation drug called Champix. Eligible participants must be 18 years or older, a daily-smoker who wishes to quit, have stable Chronic Obstructive Pulmonary Disease(COPD), and not have used Champix in the last 12 months. Associate professor Natalie Walker said quitting smoking and staying smokefree was the only intervention that would halt the rapid decline in lung function seen with COPD. Champix is currently the most effective medicine in preventing relapse in recent ex-smokers available in New Zealand. To register interest in participating call 0800 367 644, email email@example.com, or contact via Facebook @SPACEtrial.